A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
Status:
Withdrawn
Trial end date:
2020-10-19
Target enrollment:
Participant gender:
Summary
The objective of this trial is to assess anti-tumour activity of BI 754091 as monotherapy and
of BI 754091 in combination with BI 836880 in patients with unresectable or metastatic
squamous cell carcinoma of the anal canal who progressed on or after chemotherapy.